Docetaxel
Key facts
Invented name |
Taxotere
|
Active substance |
docetaxel
|
Therapeutic area |
Oncology
|
Decision number |
P/22/2008
|
PIP number |
Docetaxel
|
Pharmaceutical form(s) |
Concentrate and solvent for solution for infusion
|
Condition(s) / indication(s) |
Nasopharyngeal carcinoma
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Aventis Pharma SA
E-mail: sylvie.gabriel@sanofi-aventis.com |
Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|